At a Glance
- Precision medicine for bipolar disorder means tailoring treatment to your specific clinical profile — not starting everyone on the same first-line medication and waiting to see what happens.
- Research published in Biological Psychiatry confirms that clinicians typically select bipolar medications “through trial and error” — and that this can be optimized.
- A precision approach uses clinical history, episode patterns, comorbidities, metabolic profile, and — increasingly — pharmacogenomic data to guide medication selection.
- A JAMA 2023 review found bipolar diagnosis is delayed by an average of 9 years — and more than 50% of patients are not adherent to treatment. Both problems are addressed by individualized care.
- Precision prescribing is not a future promise. It’s a clinical methodology available now at practices built specifically for bipolar disorder.
If you’ve been on multiple bipolar medications — each one tried for months, adjusted, replaced — you know the experience that clinical researchers call “trial and error prescribing.” You’ve lived it. And for most people who’ve been through the bipolar treatment system, it’s one of the most exhausting parts.
According to a 2025 review in Biological Psychiatry, this is still how it works in most clinical settings: “Clinicians typically select mood-stabilizing medications from among several options through trial and error.” The authors go on to note that “this process could be optimized by using robust predictors of treatment response.”
That optimization is what precision medicine for bipolar disorder is about. And understanding it matters — not because it’s a future promise, but because it changes what to look for in your care right now.
If you’re wondering what care built around this approach actually looks like, schedule your first appointment with Sway Health and see for yourself.
What “Precision Medicine” Actually Means
Precision medicine — sometimes called personalized medicine or precision psychiatry — is an approach to treatment that uses individual-specific information to guide clinical decisions, rather than applying a one-size-fits-all protocol.
In other words: instead of starting everyone with bipolar disorder on the same first-line medication and titrating until something works, a precision approach asks: what do we already know about this person that would help us choose more intelligently from the start?
A 2025 review in the International Journal of Neuropsychopharmacology describes precision psychiatry as aiming “to improve routine clinical practice by integrating biological, clinical, and environmental data.” That means considering not just your diagnosis, but your full clinical picture: your episode history, your comorbidities, your metabolic profile, your medication history, and — increasingly — your genetic makeup.
This matters in bipolar disorder in particular because the condition is biologically heterogeneous. Research from 2019 describes the core problem plainly: “For bipolar disorder, the major evidences for [current treatment limitations] are the long paths before a proper diagnosis, the inconsistence of treatment guidelines, the long phases of pharmacological adjustment, and the low average of long-term treatment response rates.”
Put simply: the diagnostic and treatment journey for most people with bipolar disorder is longer and more chaotic than it should be. Precision medicine tries to fix that.
The Problem with Standard Prescribing
To understand why precision medicine matters, it helps to understand what standard prescribing looks like — and what it costs.
A 2023 JAMA review found that bipolar disorder affects approximately 8 million adults in the United States. The same review noted that “diagnosis and optimal treatment are often delayed by a mean of approximately 9 years following an initial depressive episode.” And once diagnosed, more than 50% of patients are not adherent to treatment.
Those two numbers are connected. When the path from diagnosis to the right medication takes years of adjustments — when each trial lasts months, involves side effects, and may not result in meaningful improvement — the cumulative burden is enormous. People stop trying. Or they stay on medications that are partially working but not optimized.
The unmet need is well-documented in the research: “The effective treatment, and prevention of bipolar disorder represents an area of significant unmet medical need. While more than half a century has passed since the introduction of lithium… that medication remains a mainstay.” The drugs haven’t changed dramatically. What’s changing is how we select and optimize them.
What a Precision Approach Uses
A precision prescribing approach for bipolar disorder draws on several categories of information:
Clinical History and Episode Phenotype
The most powerful predictor of medication response is your clinical history: how many episodes you’ve had, what type (manic, hypomanic, depressive, mixed), how quickly they cycle, whether there are triggers, and what has worked or failed before. This information is often underutilized in standard care because appointments are short and intake forms are blunt instruments.
Research on lithium response prediction has consistently found that certain clinical features — episodic course, absence of rapid cycling, family history of bipolar disorder, limited psychiatric comorbidities — predict better responses. That means clinical history isn’t just background information. It’s a precision tool when used properly.
Metabolic and Medical Profile
Your metabolic health affects both which medications will work and which side effects you’re likely to experience. Someone with insulin resistance or obesity carries a different risk profile with quetiapine or valproate — both of which can promote weight gain — than someone who doesn’t. A provider selecting medication without considering this is missing a key variable.
The CANMAT/ISBD 2018 guidelines — the most widely referenced international guidelines for bipolar treatment — explicitly address individualized selection based on tolerability, safety, and patient-specific factors in addition to efficacy evidence. Precision prescribing operationalizes this guidance in practice.
Pharmacogenomics
Pharmacogenomics — the study of how your genetic makeup affects how you metabolize and respond to medications — is the dimension of precision medicine that has generated the most research interest in bipolar disorder.
A review published in Molecular Diagnostics and Therapeutics summarizes the state of the field: lithium is effective “in 60% of chronically treated patients, but response remains heterogenous and a large number of patients require a change in therapy after several weeks or months.” Identifying in advance who will respond to lithium — and who won’t — is an active area of research.
A 2023 study using methylomic biomarkers correctly classified 86% of individuals according to their lithium response when clinical variables were combined with epigenetic markers. That’s meaningful. It suggests the information to predict medication response exists — the challenge is building systems to use it clinically.
An NCBI overview of pharmacogenomic testing for psychiatric disorders notes that pharmacogenomic testing has been available for approximately 20 years and examines genetic variation in medication metabolism, with the aim of guiding “personalized treatment strategies that improve therapeutic outcomes.” Several FDA-approved tests now exist for medications commonly used in bipolar disorder.
It’s worth being honest here: pharmacogenomic testing in bipolar disorder is still an emerging field. The evidence for specific tests is mixed, and no single test predicts bipolar treatment response with certainty. What it can do — especially for medications where genetic metabolism variants are well-characterized — is help avoid some adverse reactions and identify which medications are likely to be processed efficiently by your body.
What This Looks Like in Clinical Practice
A precision prescribing approach doesn’t require a futuristic clinic. It requires a clinician who:
- Conducts a thorough psychiatric history, not a 20-minute intake
- Reviews your prior medications systematically — what worked, what didn’t, what caused side effects and why
- Considers your metabolic and medical profile before selecting a first-line agent
- Tracks your response over time with enough specificity to adjust intelligently
- Stays current on the literature for the specific condition they treat
This is the difference between a generalist prescriber who treats many conditions and a bipolar-specialized clinician who treats bipolar disorder all day, every day. The latter has the pattern recognition — built from clinical experience with a specific population — to make more informed first-choice decisions.
Read what integrated bipolar treatment actually looks like and our guide to mood stabilizers for bipolar disorder to understand how this works in practice.
According to a Stanford review of precision medicine approaches, the emerging model “has the potential to mitigate some of psychiatry’s most pressing issues, including improving disease classification, lengthy treatment duration, and suboptimal treatment outcomes.” For the person who has been through three mood stabilizers and two antipsychotics in four years, that clinical trajectory is exactly what’s at stake.
Why Sway’s Approach Is Different
Sway Health is built around bipolar-specialized care — not general mental health. That specialization makes precision prescribing possible in a way that general psychiatry practices can’t replicate.
Sway’s clinical team conducts extended intake evaluations designed to capture the clinical history that informs personalized medication selection. They use what’s been called a bipolar-specific precision medicine framework: synthesizing episode history, treatment history, metabolic profile, and when appropriate, pharmacogenomic data, to make the most informed first-choice — and to adjust based on real outcomes data rather than waiting out a trial period.
The evidence on lithium provides a good example of why this matters. Lithium is effective for 60% of patients, but predicting who responds — and who doesn’t — saves months of trial time. When you’re already in a depressive episode and waiting for a medication to work, those months matter.
Sway’s internal outcome data — 50% reduction in depression symptoms at 60 days — reflects what’s possible when care is actually built for the specific condition being treated.
Is Precision Bipolar Care Right for You?
Precision medicine isn’t a buzzword. It’s a clinical approach that changes the medication selection process in meaningful ways — and it’s most relevant for:
- People who have been through multiple medication trials without finding the right fit
- People currently taking a bipolar medication that’s working partially but with significant side effects
- People newly diagnosed who want to start with the most informed clinical approach
- People whose current provider doesn’t specialize in bipolar disorder
If any of those situations sound familiar, explore bipolar treatment options with a specialist before concluding that the medication options are exhausted.
The trial-and-error approach to bipolar prescribing isn’t inevitable. It’s what happens when treatment isn’t designed specifically for this condition. Precision prescribing is one of the core reasons to see a bipolar specialist rather than a generalist — and it’s available now, without a years-long waitlist, through telehealth.
Curious whether Sway takes your insurance? Schedule your first appointment with Sway Health — you can check coverage in under two minutes, no commitment required.
